Hemophilic Arthritis
Conditions
Interventions
Hemophilia A Group / Hemophilia B Group:None
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients undergoing hip or knee arthroplasty at our hospital from January 2019 to December 2025 1. Confirmed diagnosis of hemophilia A (coagulation factor VIII activity <40%) or hemophilia B (coagulation factor IX activity <40%). 2. Presence of hemophilic arthropathy (confirmed by imaging evidence). 3. Underwent primary unilateral or bilateral total hip arthroplasty (THA) or total knee arthroplasty (TKA). 4. Complete perioperative key data (e.g., blood loss volume, clotting factor dosage, APTT results at all time points, cost breakdown, postoperative complication records, etc.).
Exclusion criteria
Exclusion criteria: 1. Concurrent presence of other coagulation disorders (e.g., von Willebrand disease (vWD), platelet dysfunction, or other inherited bleeding disorders). 2. Revision surgery (e.g., requiring secondary procedures due to periprosthetic fractures, prosthesis loosening, infection, etc.). 3. Received anticoagulant therapy (e.g., warfarin) or long-term nonsteroidal anti-inflammatory drugs (NSAIDs, such as aspirin) within 3 months prior to surgery.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Perioperative blood loss;Total perioperative consumption of coagulation factors;Perioperative Medical Costs; | — |
Secondary
| Measure | Time frame |
|---|---|
| Postoperative Functional Rehabilitation-Related Indicators;Postoperative complications and readmission rates within 90 days; | — |
Countries
China
Contacts
Public ContactYi Zeng
Department of Orthopaedics, West China Hospital, Sichuan University
Outcome results
None listed